changes in managing HD patients have probably reduced GBV-C/HGV contact in the same way.
(30 s at 94°C, 30 s at 55°C, 30 s at 72°C in a 9600 Perkin of the virus clearance [25] [26] [27] . Thus, the presence of Elmer thermocycler). GBV-C/HGV RNA amplification anti-E2 seems to testify a past GBV-C/HGV contact products were detected by a hybridization with specific and is highly associated with protection from reinfecinternal probes labelled with digoxigenin using the DIGtion [28] . Prevalence of anti-E2 antibodies has been System (Boehringer Mannheim, Germany). Our laboratory already established in several populations at risk or has participated in a GBV-C/HGV-PCR quality control [30] . not. Indeed, these antibodies were found in 3-10.9%
Positive and negative controls were included in each run of blood donors [25, 26 ] , 8 .9% in French unpaid blood and false positive results were avoided by application of donors [18] , 41-85.2% of intravenous drug users contamination prevention measures. Samples were consid- [25, 26 ] , in 25.7% of patients with clotting disorders ered positive when positive results were obtained with both primer sets starting from two independent extractions. [9] , in 12.9-29% of HD patients in Germany [14, 29] , Anti-E2 were detected by an ELISA sandwich assay (mPlate in 22% of HD patients in Vienna, Austria [15] , and in Anti-HGenv, Boehringer Mannheim). According to the 14 .2% of HD patients in Leuven, Belgium [16 ] .
manufacturer's recommendations, the positive results were
The aim of this study was to assess the prevalence assessed by a confirmatory test that excludes E2 antigen in of present or past GBV-C/HGV contact in a cohort the incubation step. of French HD patients. We compared the presence of In order to define the duration of GBV-C/HGV carriage, GBV-C/HGV with age, time on dialysis, alanine amino we investigated GBV-C/HGV viraemia in some of the HGVtransferase (ALT ) levels, co-infection with hepatitis B PCR-positive patients whose earlier available samples had virus (HBV ), HCV, and human immunodeficiency been stored in adequate conditions to perform RT-PCR. virus (HIV ). Moreover, in order to determine the Moreover, each HGV-PCR positive patient was also tested 6, 12 and 18 months after the beginning of the study for outcome of the infection, GBV-C/HGV viraemic GBV-C/HGV viraemia and for anti-E2.
patients were followed prospectively for 18 months, Statistical analysis was performed by Student-Fischer tand retrospectively when sera were stored.
test, x2 test with Yates' correction when necessary, and by the odds ratios. Differences were considered as significant when P<0.05.
Subjects and methods

Patients
Results
All 120 patients on maintenance HD in Edouard Rist Medical Center (Paris, France) were tested for GBV-C/HGV RT-PCR Prevalence of GBV-C/HGV RNA and anti-E2 enve1ope and anti-GBV-C/HGV envelope protein E2 antibodies. The protein population consisted of 75 males and 45 females. Mean age Clinical and serological data from the studied patients was 49±21 years and mean HD duration was 85±83 months.
are reported in Table 1 . Seventeen of the 120 patients Sixty-five patients were from Europe, 38 from Africa, nine (14%) were HGV-PCR positive and 18 (15%) had from Asia, and eight from America. All patients gave informed consent.
anti-E2. None of the patients were simultaneously Data on time on HD, history of transfusion, ALT levels, positive for GBV-C/HGV-RNA and anti-E2. Therepresence of HBV markers (HBsAg, HBsAb, HBcAb), HCV fore 35 (29%) of our patients had been contamined serology (anti-HCV antibodies (HCV Ab)), HCV viraemia with GBV-C/HGV. No significant difference was observed between the 17 GBV-C/HGV-viraemic and the 15 anti-E2-positive Methods patients concerning duration of haemodialysis or clinical and serological markers. Therefore the group of All serum samples were collected in January 1996, aliquoted 35 GBV-C/HGV patients has been compared with and stored at −80°C. GBV-C/HGV RNAs were extracted negative patients. GBV-C/HGV contact was statisticfrom 100 ml of serum according to a guanidium isothiocyanally correlated with the duration of dialysis: 114±76 ate-phenol method (Trizol LS, Life Technologies, USA). months compared with 73±83 months for patients cDNA synthesis of 10 ml RNA was performed using a random hexanucleotide mixture and a Mu-LV reverse tran-without GBV-C/HGV infection (Fischer's exact test scriptase (First-Strand cDNA Synthesis kit, Pharmacia, P<0.01), but not with the age. Sweden). cDNA was amplified in a 50 ml volume using a
The number of patients with an increased ALT level commercial assay (HGV Primer and Capture Probe Set, was so low (4/120), that we could not statistically Boehringer Mannheim, Germany) which includes two sets compare the two groups for this marker. Among these of primers located in the putative 5∞ non-coding region four patients with a high ALT level (range 81-100), (5∞-NCR primer-I (101-120), 5∞-CGG CCA AAA GGT only one was GBV-C/HGV viraemic. This patient was GGT GGA TG-3∞; primer-2 (285-267), 5∞-CGA CGA GCC also infected with HIV, one was free of any virus, one TGA CGT CGG G-3∞) and NS5a region (NS5a primer-1 was HCV viraemic and was treated for hepatocellular (77-101), 5∞-CTC TTT GTG GTA GTA GCC GAG AGA carcinoma, and the last one had an active hepatitis B.
T-3∞; primer-2 (152-172), 5-CGA ATG AGT CAG AGG ACG GGG TAT-3∞) [6 ] . Forty-five cycles were performed The two last patients had anti-E2. 
Co-infection with other viruses
without GBV-C/HGV markers (28% had anti-HCV ). Among the eight HIV patients present in the unit during Twenty four of the 35 GBV-C/HGV-positive patients the study period (T4=334±253/mm3), six have been in (69%) were found to be coinfccted with HBV and/or contact with GBV-C/HGV, five were viraemic (T4= HCV and/or HIIV (see Table 1 and Figure 1 ).
302±30 l/mm3), and one has developed anti-E2 (T4= There was no relationship between GBV-C/HGV 244/mm3). The GBV-C/HGV-positive patients were positivity and ongoing (HBsAg-positive individuals) or more often infected with HIV (17%) than GBV-C/HGVpast (patients with HBcAb and HBsAb) HBV infection. negative subjects (2%) (OD=8.58, IC 95%=1.6-43.6%). HBV contact was found in 45 patients (38%); 13 (11%) Seventy-five patients (62.5%) have been in contact with were positive for HBs antigen. Among these 45 subjects, GBV-C/HGV or HCV or HBV or HIV and were under 17 (14%) had contact with GBV-C/HGV and HBV. HD since 113±89 months. Forty-five (37.5%) patients Among the 43 patients with anti-HCV antibodies, 35 were free of the four studied viruses, they had been were viraemic (29% of the total ) with a known genotype, under HD for 38±39 months (P<0.001). but there were no associations with various HCV genotypes (data not shown). On the other hand, the frequency Blood transfusion of HCV carriage was significantly different (OD=3.02, IC 95% 1.3-6.9) between the group of GBV-C/HGV-Sixty-four of the 120 patients had had blood transfusions in the HD unit. The transfusion history for the positive patients (54% had anti-HCV ) and individuals 
For 12 of the 17 GBV-C/HGV RNA-positive patients, one or more samples were available for GBVwere infected with GBV-C/HGV. There was no significant difference between the group of GBV-C/HGV C/HGV RNA investigation. All of them were already GBV-C/HGV infected before the date of the first viraemic patients and the group of individuals with anti-E2 ( Table 2) . studied specimen. Two patients (nos 68 and 108) had transient GBV-C/HGV viraemia. One (no. 101) was Because HCV systematic screening was established in March 1990 in France, we looked for GBVC/HGV GBV-C/HGV-RNA negative at the end of the study without developing anti-E2. None was anti-E2 positive contact in patients transfused before 1991. In the group of 23 GBV-C/HGV-infected patient, we observed more at baseline (January 1996), but one patient (no. 68) developed these antibodies in June 1997, with persistent patients (P<0.01) with a transfusion history prior to 1991 (19/23) than after 1991 (4/23).
viraemia. Persistent GBV-C/HGV viraemia without anti-E2 was observed for all the five HIV/HGV RNA-positive Duration of GBV-C/HGV viraemia subjects (nos 1, 14, 24, 35 and 99). The follow-up for The results obtained from the detection of GBV-these patients were 18 months (2 patients). 47 months C/HGV viraemia and anti-E2 antibodies in sequential (1 patient), and 54 months (2 patients). samples involving the 17 RT-PCR GBV-C/HGV-positDuring the observation period (between January ive individuals during a follow-up retrospective and 1996 and June 1997), none of the GBV-C/HGVprospective study are given in Table 3 . A persistent infected patients developed biochemical or clinical viraemia was observed at the end of the study period signs of hepatitis or other symptoms not attribuable to the underlying disease. A past or present GBV-C/HGV infection was found in 29% of the 120 patients on chronic HD in our found a contact rate for GBV-C/HGV in HD patients in peripheral blood mononuclear cells. Thus, the described prevalence of GBV-C/HGV contact may be of 23% (7/31), 35% (25/72), 34% (40/119), and 28.6% (32/112) respectively. actually at least partly underestimated. Contrary to the studies on GBV-C/HGV viraemic In our study, 14% of HD patients were found to be GBV-C/HGV viraemic. This prevalence is comparable HD patients [12, 16 ] [11] , but less than those found in a previous French study [13] , should allow a reduction of GBV-C/HGV transmission in HD patients. Thirty eight per cent of the patients which reported a HGV-RNA-positive rate of 57.5%. It can be assumed that these discrepancies are caused in this study were free of HCV, HBV, GBV-C/HGV, and HIV contact and were yet haemodialysed for more by the nucleic acid amplification method applied. However, altogether these data confirm that the preval-than 3 years, suggesting that theses rules are efficient.
Moreover, the screening and elimination of anti-HCV ence of GBV-C/HGV infection is higher in HD patients than in healthy individuals like blood donors (14% of positive donations since March 1990 in France has reduced not only transfusion-transmitted HCV infec-HD studied subjects were GBV-C/HGV RNA positive vs 3.3% of 2548 unpaid blood donors in France [18] . tion, but probably also concomitant GBV-C/HGV transmission. Indeed, patients transfused in our centre On the contrary, a similar prevalence of anti-E2 is observed in this HD population when compared to before 1991 were more frequently contaminated by GBV-C/HGV than patients who were transfused after healthy controls (15 vs 8.9% in blood donors [18] ). This observation suggests that the resolution of GBV-1991 (P<0.01). Similar observations have been made in a Belgium HD unit [32] . Blood transfusion might C/HGV infection in immunosuppressed HD patients might be less efficient than in healthy subjects. In be incriminated in transmission of GBVC/HGV infection in our study. Indeed, at least 66% (23/35) accordance with this hypothesis, we can point out that 16 of 17 GBV-C/HGV-viraemic patients were still GBV-C/HGV-positive patients received transfusions.
Unfortunately, for the 56 patients who did not receive GBV-C/HGV RT-PCR positive after 18 months follow up. One became GBV-C/HGV-RNA negative, but in transfusions, we have no information concerning a transfusion history before their arrival at the centre. the absence of anti-E2, we cannot differentiate a resolved infection from a transient viraemia.
Consequently, it was not possible to compare the transfused and not transfused populations. Twelve of 17 patients in whom earlier serum samples were available were also GBV-C/HGV RNA positive Transmission of GBVC/HGV by blood transfusion is not supported by the findings of Schulte-Frohlinde for the first tested serum. Thus, the minimal duration was between 18 and 78 months. This high level of [29] who did not show correlation between GBV-C/HGV contact and history of blood transfusions. In GBV-C/HGV chronic carriers would be partly imputed to a centre effect due to the presence of five HIV GBV-fact, other parenteral routes of transmission may contribute to the higher rates of GBV-C/HGV infection C/HGV-viraemic patients, in regards to the epidemiology of HIV infection in HD patients in France [31] . in HD patients.
Time on HD appears to be a statistically significant However, the average of follow-up delay for HIV patients was not higher than that observed in non-factor for being exposed to GBV-C/HGV in our study.
This result is in accordance with some reports HIV population (38.2 vs 48.7 months), and long, chronic GBV C/HGV infection in HD patients has [13, 14, 29] , but not in others [10, 12, 15, 16 ] . It must be stressed that, as shown by of Szabo et al. [14] , GBVbeen described [4, 10] in a period over 16 years [4] .
All 18 patients found positive for anti-E2 at the C/HGV RNA-positive patients were on haemodialysis for a longer time. All these data are in accordance beginning of the study were GBV-C/HGV RT-PCR negative. One of the 17 initially GBV-C/HGV with the hypothesis that the incidence of GBV-C/HGV infection is decreasing, thanks to the combined effects RT-PCR-positive patient has developed anti-E2 while keeping a positive GBV-C/HGV RT-PCR. It might of a better selection of blood donors, the elimination of HCV-positive blood products, the extensive use of well be that this patient is going to resolve GBV-C/HGV infection during further follow up. These data erythropoietin, and the application of the universal rules of prevention of parenteral contact in dialysis confirm that the presence of anti-E2 is associated with recovery from GBV-C/HGV infection.
units. Only one out of the 17 patients GBV-C/HGV viraOne initially GBV-C/HGV-viraemic patient became GBV-C/HGV RNA negative without appearance of emic from our centre had a high ALT level, this patient was HIV positive. This suggests that GBV-C/HGV is anti-E2 antibodies, suggesting that a combined detection of GBV-C/HGV RNA and anti-E2 can miss a poorly or not hepatotoxic. GBV-C/HGV has been implicated in the aetiology of hepatitis [33] and aplastic few patients that have been exposed to GBV-C/HGV. Similarly, Tribl et al. [15] and Sheng et al. [9] identified anaemia [34, 35] , but more recent epidemiological studies suggested that GBV-C/HGV has only a limited a few serum GBV-C/HGV RT-PCR negative patients in whom GBV-C/HGV RNA could be demonstrated disease-inducing potential [4, 20, 36 ] 15. Tribl B, Oesterreicher C, Pohanka E et al. GBV-C/HGV in
In conclusion, prevalence of exposure to GBVhemodialysis patients: Anti-E2 antibodies and GBV-C/RNA in C/HGV is high in HD patients, and correlated to HCV 
